Case Study: Leading Orphan and Rare Disease Manufacturer achieves seamless IV-to-SC launch continuity with IntegriChain (Blue Fin Group)

Maintaining Patient, Provider and Product Continuity at Commercial Launch

Leading Orphan and Rare Disease Product Manufacturer faced a critical IV-to-SC transition for its first subcutaneous formulation to meet unmet patient needs and respond to emerging competition, requiring a complete distribution and dispensing strategy, patient training/support, and accelerated implementation within a twelve-month launch window. IntegriChain (through Blue Fin Group) was engaged to help, leveraging its patient services and case management platform and expertise in channel strategy and commercial launch planning.

IntegriChain delivered a comprehensive distribution and dispensing channel strategy, a robust business rationale, and a detailed multi‑generational implementation plan that aligned commercial stakeholders, supported patient self-administration training, and preserved continuity across sites of care and benefit designs. The work gave the Leading Orphan and Rare Disease Product Manufacturer a clear path for the IV-to-SC transition, increased organizational confidence, and enabled acceleration of the commercial plan and go-to-market timing while maintaining a best-in-class patient experience.